Johnson & Johnson boasts a vast portfolio and a rock-solid balance sheet. AbbVie's main growth pillars are posting impressive ...

It's hard to argue against its reliability.

A Baltimore jury ordered Johnson & Johnson and its subsidiaries to pay over $1.5 billion to a woman who claimed decades of exposure to asbestos in the company’s talc-based products caused her ...

A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD ...

Johnson & Johnson's Tom Aelbrecht, N-VA's Jan Jambon, Flemish Minister for Welfare and Culture Caroline Gennez, Deputy department head of the nursing department Siska Van den Bergh, ZAS president Els ...

Three name-brand diabetes drugs and a blood thinner are now available at a discount on the government platform and J&J's own ...

Johnson & Johnson is collating its pantheon of medtech brands under a single banner, to further simplify the company’s presentation. Going forward, the conglomerate’s Ethicon, DePuy Synthes, Biosense ...

New Jersey's Johnson & Johnson grew from one ambitious pharmacist to a $94 billion pharmaceutical and medical device giant.

Add Yahoo as a preferred source to see more of our stories on Google. On Sept. 29, 1982, Mary Kellerman woke up feeling sick. The 12-year-old girl from Elk Grove Village, a suburb of Chicago, asked ...

Drug-making giant Johnson & Johnson will officially start marketing four of its medications on the Trump administration's ...

Advances Company’s industry-leading portfolio in mental health with addition of CAPLYTA ® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an ...

On Sept. 29, 1982, Mary Kellerman woke up feeling sick. The 12-year-old girl from Elk Grove Village, a suburb of Chicago, asked her parents to stay home from school, and they gave her one ...